| 21 | 0 | 280 |
| 下载次数 | 被引频次 | 阅读次数 |
相火在人体生命活动中不可或缺，相火妄动是疾病的关键始动因素，其所致气阴耗伤与慢性炎症、核因子κB(nuclear factor-kappa B,NF-κB)持续激活及肿瘤免疫逃逸等分子事件高度一致。痰瘀相互胶结，形成肿瘤，贯穿肿瘤发生发展的全程，与肿瘤微环境纤维化、细胞外基质（extracellular matrix,ECM）重塑、上皮-间充质转化（epithelial mesenchymal transition,EMT）诱导及转移前微环境构建等病理过程密切相关。“燮理相火、化痰逐瘀、益气养阴”三维干预策略，可在改善证候、调控肿瘤微环境与延缓疾病进展方面展现重要临床价值。本文从传统病机与现代机制的交叉视角，提出了肺鳞癌中医病机阐释的新框架，为中西医结合治疗策略的优化提供了理论依据与临床参考。
Abstract：The concept of ministerial fire(Xianghuo) represents an indispensable component of human physiological activity. Its pathological hyperactivity is regarded as a pivotal initiating factor for disease,and the consequent consumption of qi and yin corresponds closely with molecular events such as chronic inflammation,sustained activation of nuclear factor-kappa B(NF-κB),and tumor immune evasion. The mutual congealment of phlegm and blood stasis contributes to tumor formation and progression,aligning with pathological processes such as tumor microenvironment fibrosis, extracellular matrix(ECM) remodeling, epithelial-mesenchymal transition(EMT) induction,and the establishment of pre-metastatic niches. The three-dimensional strategy of “regulating ministerial fire,resolving phlegm and dispersing stasis,and replenishing qi while nourishing yin” demonstrates notable clinical value in syndrome improvement,tumor microenvironment modulation,and disease-progression delay. By integrating classical traditional Chinese medicine(TCM) pathogenesis with modern mechanistic insights,this article proposes a novel framework for elucidating TCM pathogenesis of pulmonary squamous cell carcinoma and offers a theoretical foundation and clinical reference for optimizing integrative TCM-Western medical treatment strategies.
[1]任玉乐，贾先红.少阳相火妄动致癌理论初探[J].浙江中医杂志，2016,51(7):471-472.
[2]吴子婷，杨永，高宠，等.基于“君火以明，相火以位”防治恶性肿瘤[J].山东中医杂志，2024,43(6):562-566.
[3]李巧凤，吴承玉.痰瘀理论源流考[J].中华中医药杂志，2024,39(12):6338-6341.
[4]傅晓青，代周娟，夏涛涛，等.肺癌病理分型与中医证型的相关性分析[J].浙江中医杂志，2024,59(7):603-604.
[5]菅佳宁，陈玉龙，李若菡，等. 2027例食管鳞癌患者中医证候分布规律[J].中国实验方剂学杂志，2025,31(15):173-181.
[6]吴冬梅，刘倩，龚婷婷，等.宫颈病变中湿热证分布及其与miR-10b表达的相关性研究[J].中医药信息，2021,38(11):62-65.
[7]SOCINSKI M A, OBASAJU C, GANDARA D, et al.Clinicopathologic features of advanced squamous NSCLC[J]. J Thorac Oncol,2016,11(9):1411-1422.
[8]孙铜林，刘华，王理槐，等.刘华从“正虚伏毒”理论维持治疗Ⅳ期肺鳞癌的经验[J].湖南中医杂志，2024,40(6):40-43.
[9]黄金昶.黄金昶肿瘤专科二十年心得[M].北京：中国中医药出版社，2012:5.
[10]王小燕，王丽敏，何文静，等.沙冬温阳方辅助化疗治疗晚期肺鳞癌气阴两虚、痰瘀互结证39例[J].环球中医药，2024,17(9):1864-1867.
[11]樊华.中晚期周围型肺癌临床分期病理分型与中医证型相关性分析[J].亚太传统医药，2014,10(23):66-67.
[12]张政委.李氏肺鳞癌方治疗晚期肺鳞癌（痰热瘀结型）的临床疗效观察[D].成都：成都中医药大学，2024.
[13]吴炳辰，许建新，王燕山.从朱丹溪“气、血、痰、郁”学术思想论治肺癌探析[J].江苏中医药，2017,49(6):8-9.
[14]陈惠，龚婕宁，渠景连.以中医络病理论试论恶性肿瘤发病及其转移的病机证治[J].广州中医药大学学报，2014,31(6):1012-1015.
[15]NIU Z Y, JIN R S, ZHANG Y, et al. Signaling pathways and targeted therapies in lung squamous cell carcinoma:Mechanisms and clinical trials[J]. Signal Transduct Target Ther,2022,7(1):353.
[16]LAU S C M, PAN Y W, VELCHETI V, et al. Squamous cell lung cancer:Current landscape and future therapeutic options[J].Cancer Cell,2022,40(11):1279-1293.
[17]MARTEY C A,POLLOCK S J,TURNER C K,et al. Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts:Implications for lung inflammation and cancer[J]. Am J Physiol Lung Cell Mol Physiol,2004,287(5):L981-L991.
[18]RODRÍGUEZ-ROISIN R, SORIANO J B. Chronic obstructive pulmonary disease with lung cancer and/or cardiovascular disease[J]. Proc Am Thorac Soc,2008,5(8):842-847.
[19]ANTONANGELI F, NATALINI A, GARASSINO M C, et al.Regulation of PD-L1 expression by NF-κB in cancer[J]. Front Immunol,2020,11:584626.
[20]GUO R,LI Y,WANG Z J,et al. Hypoxia-inducible factor-1αand nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells[J].Cancer Sci,2019,110(5):1665-1675.
[21]ZHAO J L,WANG X,MI Z Y,et al. STAT3/miR-135b/NF-κB axis confers aggressiveness and unfavorable prognosis in nonsmall-cell lung cancer[J]. Cell Death Dis,2021,12(5):493.
[22]WONG K K, JACKS T, DRANOFF G. NF-kappaB fans the flames of lung carcinogenesis[J]. Cancer Prev Res,2010,3(4):403-405.
[23]LI L W, HAN L, SUN F, et al. NF-κB RelA renders tumor-associated macrophages resistant to and capable of directly suppressing CD8+T cells for tumor promotion[J]. Oncoimmunology,2018,7(6):e1435250.
[24]ZHANG H F, JIANG H, ZHU L C, et al. Cancer-associated fibroblasts in non-small cell lung cancer:Recent advances and future perspectives[J]. Cancer Lett,2021,514:38-47.
[25]WAN X Y, GUAN S D, HOU Y X, et al. FOSL2 promotes VEGF-independent angiogenesis by transcriptionnally activating Wnt5a in breast cancer-associated fibroblasts[J]. Theranostics,2021,11(10):4975-4991.
[26]SHINTANI Y,FUJIWARA A,KIMURA T,et al. IL-6 secreted from cancer-associated fibroblasts mediates chemoresistance in NSCLC by increasing epithelial-mesenchymal transition signaling[J]. J Thorac Oncol,2016,11(9):1482-1492.
[27]BARBAZAN J, PÉREZ-GONZÁLEZ C, GÓMEZ-GONZÁLEZ M, et al. Cancer-associated fibroblasts actively compress cancer cells and modulate mechanotransduction[J]. Nat Commun,2023,14(1):6966.
[28]SUH J,KIM D H,LEE Y H,et al. Fibroblast growth factor-2,derived from cancer-associated fibroblasts,stimulates growth and progression of human breast cancer cells via FGFR1 signaling[J].Mol Carcinog,2020,59(9):1028-1040.
[29]NASR M M,LYNCH C C. How circulating tumor cluster biology contributes to the metastatic cascade:From invasion to dissemination and dormancy[J]. Cancer Metastasis Rev,2023,42(4):1133-1146.
[30]富琦，张晨曦，杨国旺，等.恶性肿瘤患者凝血指标临床分析及其与血瘀证的相关性[J].中医杂志，2011,52(23):2024-2026,2030.
[31]YU T C,TANG B,SUN X Y. Development of inhibitors targeting hypoxia-inducible factor 1 and 2 for cancer therapy[J]. Yonsei Med J,2017,58(3):489-496.
[32]WILSON W R,HAY M P. Targeting hypoxia in cancer therapy[J].Nat Rev Cancer,2011,11(6):393-410.
[33]ZHAO Y, XING C, DENG Y T, et al. HIF-1α signaling:Essential roles in tumorigenesis and implications in targeted therapies[J]. Genes Dis,2024,11(1):234-251.
[34]庞皓玥，胡凯文，孙满强，等.川芎嗪通过减少肺癌A549细胞内活性氧的生成抑制细胞增殖及侵袭[J].现代肿瘤医学，2021,29(21):3695-3699.
[35]朱纪烨.补阳还五汤对乏氧微环境下肺癌A549细胞的作用及其中相关蛋白基因表达的调控机制研究[D].长沙：湖南中医药大学，2021.
[36]王博文，裴紫娟，宋凡，等.基于HIF-1α信号轴探讨中医药干预肺癌的机制研究进展[J/OL].中国实验方剂学杂志，1-19[2026-03-16]. http://doi.org/10.13422/j.cnki.syfjx.20251926.
[37]GASPARINI G,LONGO R,TOI M,et al. Angiogenic inhibitors:A new therapeutic strategy in oncology[J]. Nat Clin Pract Oncol,2005,2(11):562-577.
[38]MCDONALD D M,MUNN L,JAIN R K. Vasculogenic mimicry:How convincing, how novel, and how significant?[J]. Am J Pathol,2000,156(2):383-388.
[39]FUKUMURA D, JAIN R K. Imaging angiogenesis and the microenvironment[J]. APMIS,2008,116(7-8):695-715.
[40]JACKSON A L,ZHOU B,KIM W Y. HIF,hypoxia and the role of angiogenesis in non-small cell lung cancer[J]. Expert Opin Ther Targets,2010,14(10):1047-1057.
[41]姜紫阳，陈巍.基于“瘿瘤”伏邪理论探讨痰瘀毒结与免疫微环境失衡对甲状腺癌复发转移的作用机制[J].中医临床研究，2025,17(35):21-25.
[42]易琼，彭清华，郭志华，等.心痛泰对痰瘀互结证腹主动脉易损斑块模型兔病理性血管新生及HIF-1 α/VEGF/VEGFR2信号通路的影响[J].中医杂志，2023,64(2):159-166.
[43]THAPA R, GUPTA S, GUPTA G, et al. Epithelial-mesenchymal transition to mitigate age-related progression in lung cancer[J]. Ageing Res Rev,2024,102:102576.
[44]YAN T T,SHI J H. Angiogenesis and EMT regulators in the tumor microenvironment in lung cancer and immunotherapy[J]. Front Immunol,2024,15:1509195.
[45]SCHÄFER G, NARASIMHA M, VOGELSANG E, et al.Cadherin switching during the formation and differentiation of the Drosophila mesoderm-implications for epithelial-to-mesenchymal transitions[J]. J Cell Sci,2014,127(Pt 7):1511-1522.
[46]TIRPE A A, GULEI D, CIORTEA S M, et al. Hypoxia:Overview on hypoxia-mediated mechanisms with a focus on the role of HIF genes[J]. Int J Mol Sci,2019,20(24):6140.
[47]LÓPEZ-NOVOA J M,NIETO M A. Inflammation and EMT:An alliance towards organ fibrosis and cancer progression[J]. EMBO Mol Med,2009,1(6-7):303-314.
[48]李建省，司富春.肿瘤细胞凋亡的中医阴阳理论阐释[J].辽宁中医杂志，2010,37(6):1034-1035.
[49]周妮娜，刘永琦，张利英，等.从中医阴阳平衡探讨辐射诱发细胞基因组不稳定性及益气滋阴法防护机制[J].中华中医药杂志，2016,31(11):4711-4713.
[50]张广辉，何姝霖，李丛煌，等.基于《黄帝内经》构建“肿瘤阴阳气化”模型并探讨调气解毒法的学术内涵[J].中华中医药杂志，2024,39(6):2757-2763.
[51]王玥，张甘霖，赵维哲，等.基于“凡动皆属火”辨治恶性肿瘤[J].世界中医药，2023,18(20):2924-2927.
[52]宁麟，孙建光.原发性肝癌癌前病变中西医研究进展[J].世界科学技术-中医药现代化，2021,23(10):3590-3598.
[53]阮广欣，周蕾.益气养阴方通过p53依赖AKT/NF-κB信号传导抑制肺癌细胞增殖研究[J].亚太传统医药，2019,15(10):32-36.
[54]张艳，张彩丽，刘燕，等.黄芩苷通过NF-κB信号对气道上皮黏液调节因子MUC5AC和CFTR表达的影响[J].陆军军医大学学报，2022,44(5):441-447.
[55]陶斯雨，李亚，陈锴，等.中药活性成分、复方通过NF-κB信号通路干预急性肺损伤的研究进展[J].中药药理与临床，2025,41(8):98-105.
基本信息:
DOI：10.19811/j.cnki.ISSN2096-6628.2026.03.003
中图分类号:R273
引用信息:
[1]孙铜林,邓瑶,王立亚,等.从丹溪“相火-痰瘀”理论论治肺鳞癌的学术探究与临床实践[J].中医肿瘤学杂志,2026,8(02):13-21.DOI:10.19811/j.cnki.ISSN2096-6628.2026.03.003.
基金信息:
2026年度湖南省自然科学基金项目（编号：2026JJ82466）; 2025年度湖南省教育厅资助科研项目（编号：25C0217）; 2025年度湖南中医药大学校院联合基金项目（编号：2025XYLH013）; 2024年度湖南省中医药管理局中医药科研课题（编号：B2024053）; 湖南省中医肿瘤临床医学研究中心项目（编号：2021SK4023）
2026-03-25
2026-03-25